OP0083 MOLECULAR TARGETED IMAGING BIOMARKERS FOR PERSONALIZED MEDICINE STRATEGIES IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
Background: Interstitial lung disease (ILD) is a life-threatening complication in systemic sclerosis (SSc). Substantial research progress has identified distinct genomic and molecular subtypes in SSc-ILD and brought molecular targeted therapies within reach. However, personalized medicine approaches are still lacking since clinically applicable tools for individualized patient stratification are not yet available. Objectives: To assess the possibility of imaging molecular targets as a biomarker for stage-dependent assessment of ILD in the mouse model of bleomycin-induced lung fibrosis. Methods: Expression of integrin α v β 3 and folate receptor β (FR-β) was analyzed in lung tissues from patients with idiopathic pulmonary fibrosis (IPF), SSc-ILD, and healthy controls as well as from bleomycin treated mice and saline treated controls using immunohistochemistry and qPCR (n=5-11). SPECT (Single Photon Emission Computed Tomography) or PET (Positron Emission Tomography) was performed at days 3, 7, and 14 after bleomycin instillation using the integrin α v β 3 -specific 177 Lu-c(RGDfK)-ligand and the FR-β-specific 18 F-Azafol. Additionally, 18 F-FDG-PET and high resolution CT (HRCT) scans were performed. The specific lung uptake of the radiotracers over time was assessed by ex vivo SPECT or PET/CT scans and biodistribution studies. Results: Expression of FR-β was significantly increased at the mRNA and protein level of SSc-ILD patients as compared to healthy subjects (p<0.05), whereas only its gene expression was upregulated in IPF patients (p<0.01). Integrin α v β 3 was increased at the protein level of both SSc-ILD and IPF patients (p<0.05), while its mRNA expression was not significantly altered. Similarly, in lungs of bleomycin treated mice, but not of controls, FR-β expression was increased time-dependently at the mRNA and protein level with higher expression at day 3 and day 7, the inflammatory stages of bleomycin-induced lung fibrosis (p<0.05). In contrast, expression of integrin α v β 3 was upregulated at day 7 and day 14 at the protein, but not at the mRNA level in bleomycin treated mice, and thus not only in the inflammatory but also in the fibrotic stages (p<0.05). 18 F-FDG-PET and HRCT detected time-dependent changes of metabolic activity and ILD morphology in bleomycin treated mice. However, compared with these routinely employed unselective imaging techniques, molecular targeted imaging of integrin α v β 3 and FR-β successfully visualized ILD and discriminated lung inflammation and/or fibrosis in a time-dependent manner and in correspondence with the expression changes at the tissue level. The specific lung uptake of 177 Lu-c(RGDfK)-ligand and 18 F-Azafol as compared with the unspecific uptake of 18 F-FDG in diseased lungs over time was demonstrated by biodistribution studies and ex vivo SPECT or PET/CT scans. Conclusions: Our data suggest that stage-dependent visualization of ILD with radiotracers that target key markers of lung inflammation and/or fibrosis shows promise for clinical application. As opposed to unselective imaging techniques such as 18 F-FDG-PET and HRCT, the introduction of specific imaging biomarkers for individualized management of SSc-ILD patients could represent the first step towards precision medicine. Background: The majority of Systemic Sclerosis (SSc) patients have subclinical primary cardiac involvement, which resembles the inflammatory dilated cardiomyopathy (iDCM) with inflammation and fibrosis. Firstly, cellular progenitors of pathological myofibroblasts remain undescribed. Secondly, autophagy may favor fibrosis through enhanced differentiation of fibroblasts in myofibroblasts Objectives: To unravel the role of Fos-related antigen 2 (Fra2)/autophagy crosstalk in TGF-β-driven myocardial fibrosis in SSc Methods: Genetically modified mice overexpressing Fra2 were used. Endomyocardial biopsies (EMBs) from SSc/iDCM patients and hearts from Fra2 tg and control mice were analysed by immunohistochemistry (IHC) and immunofluorescence (IF). Murine myocardial gp38 + (podoplanin + ) stromal cells were sorted and stimulated in vitro with TGF-β. The cellular phenotype was assessed by qPCR, IF, stress fiber staining, SIRCOL and contraction assay on sorted cells. The antisense oligonucleotide GapmeR was used to knock-down Fra2 Results: The myocardium of SSc/iDCM patients (n=10) showed the typical phenotype of iDCM: increased fibrotic area with extended collagen deposition and enlarged number of pathological myofibroblasts, expressing Fra2 and, interestingly, the autophagy markers LC3B and Atg5. Similarly, Fra2 tg mice showed higher expression of profibrotic markers: αSMA, vimentin and collagen I compared to control mice (n=5), as well as the expression of the autophagy markers LC3B and Beclin in fibrotic regions. Among cardiac stromal cells (Ter119 -CD45 -CD31 -Sca1 + CD29 + ) the frequency of gp38 + cells was significantly higher in Fra2 myocardium compared to control mice. The majority of gp38 + cells co-expressed αSMA, vimentin and collagen I together with autophagy markers (LC3B and Beclin, n=3). Following in vitro stimulation with TGF-β, gp38
+ cells entered fibroblast-to-myofibroblast transition characterized by increased mRNA and protein levels of αSMA, collagen I, fibronectin (n=3-6), αSMA-fiber and stress-fiber formation (n=3), increased cell proliferation (n=4; p=0.04) and contraction capability (n=2; p<0.05) and enhanced collagen secretion (n=3; p=0.04). Importantly, Fra2 tg gp38 + cells showed the presence of αSMA and stress fibers even without TGF-β stimulation as well as an increased contraction capability compared to control cells. TGF-β stimulation of control gp38 + cells induced the expression of LC3B, Beclin and Atg5 at mRNA and protein level (n=3-5). In contrast, TGF-β inhibition caused the downregulation of these markers (n=3). In addition, Fra2 silencing resulted in a decreased differentiation capability of
